Trials / Completed
CompletedNCT00954642
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | Intravenous repeating dose |
| DRUG | MNRP1685A | Escalating intravenous dose |
| DRUG | paclitaxel | Intravenous repeating dose |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2009-08-07
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT00954642. Inclusion in this directory is not an endorsement.